On October 28, 2025, Eli Lilly announced a major collaboration with NVIDIA to build the industry's most powerful AI supercomputer, aiming to accelerate drug discovery and development. The new system, powered by over 1,000 NVIDIA B300 GPUs, will serve as an 'AI factory' to manage the entire AI lifecycle, enabling rapid learning and innovation across Lilly's research, manufacturing, and enterprise operations[2]. Despite this major announcement, LLY shares traded lower at $819.01 (-0.90%) as of 2:54 PM EST, underperforming the broader market, which was up moderately. The stock's decline suggests the news may not have immediately offset other market or sector factors, but the partnership is positioned as a transformative step for Lilly's long-term innovation strategy.